Sapio Sciences

Sapio Sciences is a laboratory informatics software company founded in 2004 by Kevin Cramer, headquartered in Baltimore, Maryland. The company develops cloud-based LIMS (Laboratory Information Management System), ELaiN (AI-native electronic lab notebook), and Scientific Data Cloud (SDMS) solutions for life science research, diagnostics, and pharmaceutical manufacturing organizations. It was originally founded to address genotyping needs and Genome Wide Association Studies data analysis, and has since expanded into a lab informatics platform serving pharmaceutical, biotechnology, clinical diagnostics, and contract research organizations (CROs/CDMOs) across the drug development lifecycle.

GHO Capital Partners, a private equity firm specializing in healthcare and life sciences investments, acquired Sapio Sciences in the 2022–2023 timeframe. The company completed a Seed funding round in December 2022 (amount undisclosed) following the acquisition. Sapio operates with 103 employees (as of September 2025) across three continents: North America, Europe, and Asia.

The company's platform unites LIMS, ELaiN, and Scientific Data Cloud on a shared native AI foundation; Sapio describes it as an "agentic AI lab informatics platform" with AI co-scientist capabilities integrated throughout. In October 2024, Sapio added Electronic Batch Records (EBR) functionality to its GMP LIMS solution, enabling pharmaceutical manufacturers to track batch manufacturing processes alongside laboratory workflows in a unified system. Named customers on the platform include Oxford Biomedica, Genentech, BioNTech, Charles River, PTC Therapeutics, and Caris Life Sciences.

No-code configurability lets scientists define workflows without programming. Compliance certifications include SOC 2 Type II, ISO 27001, HDS, and EU-US DPF. Sapio LIMS carries a G2 rating of 4.5/5. The company markets unified data management through a living knowledge graph with full searchability across LIMS, ELN, and SDMS modules.

Pharmaceutical and biotechnology organizations are a core market segment for Sapio Sciences, alongside clinical diagnostics and contract research organizations. The platform supports the drug lifecycle from discovery through manufacturing, with GMP-compliant solutions for regulated pharmaceutical environments. In October 2024, Sapio added Electronic Batch Records (EBR) functionality to its unified GMP LIMS platform, enabling pharmaceutical manufacturers to track batch production processes alongside laboratory quality-control workflows.

Disclosed pharmaceutical and biotech customers include Oxford Biomedica (OXB), Genentech, BioNTech, PTC Therapeutics, Charles River (CRO), Caris Life Sciences (clinical diagnostics), Evitria, LabConnect, and Schrödinger, spanning Big Pharma, biotech, contract research organizations, and clinical diagnostics providers. The customer base includes companies throughout the United States, with additional presence in Europe and Japan.

Sapio holds GxP-compliant solutions with GLP and GCP validation; 21 CFR Part 11 and EU Annex 11 compliance for electronic records and signatures; SOC 2 Type II certification (examined by Schellman & Company, completed September 2023, covering the November 2022–June 2023 period for security, availability, and confidentiality); ISO 27001 Information Security Management System certification; HDS (Hébergement de Données de Santé) certification for French healthcare data hosting; and EU-US Data Privacy Framework certification. Out-of-the-box templates cover GMP manufacturing, clinical diagnostics, bioanalytical studies, and stability testing.

Sapio Sciences is privately held, owned by GHO Capital Partners, a private equity firm specializing in healthcare and life sciences investments. GHO Capital acquired the company in the 2022–2023 timeframe; a Seed funding round completed in December 2022 (amount undisclosed per Crunchbase). Before the acquisition, Sapio operated as an independent software company founded in 2004.

Annual revenue is undisclosed. The company has continued to win pharmaceutical and biotech customers, including Genentech, BioNTech, and Oxford Biomedica, and continued product development with the October 2024 launch of EBR functionality. In 2025 it announced partnerships with NVIDIA BioNeMo (AI integration), LabConnect, and Schrödinger. It holds SOC 2 Type II, ISO 27001, and HDS certifications.

Sapio Sciences' product portfolio centers on an integrated AI-native lab informatics platform, uniting three core modules on a shared foundation: Sapio LIMS (Laboratory Information Management System), Sapio ELaiN (Electronic Lab Notebook with agentic AI co-scientist), and Sapio Scientific Data Cloud (SDMS for enterprise scientific data management). The architecture operates as a living knowledge graph with full searchability and contextualization across all modules.

Sapio LIMS is a no-code, configurable system that lets scientists define laboratory workflows without programming. Specialized implementations include Sapio GMP LIMS for quality control, manufacturing, and bioprocessing in regulated environments; clinical and molecular diagnostics LIMS; bioanalytical studies management; and stability testing applications. The October 2024 addition of Electronic Batch Records (EBR) functionality integrates batch manufacturing process tracking directly within the LIMS platform, providing visibility from raw materials through final QC.

Sapio ELaiN is a third-generation AI-native electronic lab notebook with agentic AI co-scientist capabilities embedded across all functions, real-time collaboration, and reusable scientific objects. Built-in scientific tools include CRISPR editing, plasmid design, flow cytometry, NGS (next-generation sequencing), and 3D plating. Sapio Scientific Data Cloud (SDMS) unifies scientific data into a searchable, contextualized knowledge graph accessible across research, development, and manufacturing teams.

The product strategy centers on no-code configurability for scientists rather than IT teams, native AI integration for automation and data analysis, and modular deployment: LIMS, ELN, and SDMS can be implemented independently or as an integrated suite. In 2025 the company added partnerships with NVIDIA BioNeMo for AI enhancements and Schrödinger for molecular modeling integration.

Sapio Sciences develops technology and ecosystem partnerships to extend platform capabilities. In 2025 it announced NVIDIA BioNeMo integration for AI-powered bioinformatics, a LabConnect collaboration for clinical trial laboratory services, and a Schrödinger partnership for computational molecular modeling integration.

The company delivers the platform as SaaS; the underlying hosting provider (AWS, Azure, or Google Cloud) is undisclosed. Industry affiliations include participation in SapioCon 2025, the company's user conference.

Sapio Consulting, the company's professional services arm, provides implementation and consulting services: deployment support, workflow configuration, and validation assistance. No system integrator or channel partner network is publicized.

Sapio Sciences provides professional services through Sapio Consulting: implementation, deployment support, workflow configuration, training, and validation assistance for GxP environments. G2 reviews highlight "the quality and responsiveness of the support team" as a reason for successful implementation, describing a "friendly and experienced approach" and "willingness to work with clients" through deployment and ongoing operations (Verified reviewers, G2).

The platform's no-code configurability lets scientists modify workflows independently. Sapio also provides technical support for platform issues and advanced configurations. Support availability details — 24/7 coverage, regional support centers, multilingual capabilities, SLA commitments — are undisclosed.

Sapio hosts SapioCon 2025, an annual user conference offering educational content, best-practice sharing, and networking. G2 reviewers describe the platform as one that "could be easily implemented within their companies" due to "out-of-the-box features" and a clear user interface (Verified reviewers, G2). The company publishes webinars, product documentation, and blog content. No certification program for Sapio platform expertise is disclosed.

Sapio Sciences holds SOC 2 Type II (examined by Schellman & Company, completed September 2023, covering November 2022–June 2023), ISO 27001 (Information Security Management System), HDS (Hébergement de Données de Santé, for French healthcare data hosting), and EU-US Data Privacy Framework certification.

Founder and CEO Kevin Cramer has 20+ years in laboratory informatics. GHO Capital Partners, a private equity firm specializing in healthcare and life sciences investments, owns the company. Named customers include Genentech (Roche), BioNTech (COVID-19 vaccine developer), Oxford Biomedica, and PTC Therapeutics.

Sapio LIMS carries a G2 rating of 4.5/5; reviews cite customization capabilities, a user-friendly interface, and support quality. The company publishes a blog post titled "6 of the Worst LIMS Reviews on G2." It hosts SapioCon 2025 and has announced partnerships with NVIDIA and Schrödinger. There is no Gartner Magic Quadrant placement or other major industry analyst award.

Sapio Sciences' website (sapiosciences.com) includes product information, customer testimonials, compliance credentials, educational resources, and a demo-request form. Solution pages cover LIMS, ELN, SDMS, and EBR modules, alongside customer success stories, blog articles, and technical documentation. A resource center provides whitepapers, webinars, and company overview materials.

The company's LinkedIn page has 15,100 followers. 2025 content includes news of the EBR launch (October 2024), partnership announcements (NVIDIA BioNeMo, LabConnect, Schrödinger), and SapioCon 2025 event promotion. Press releases cover major product launches, partnerships, and compliance certifications, including SOC 2 Type II.

Market positioning uses the messaging "Simplifying Lab Informatics" and "At the heart of science," targeting pharmaceutical, biotech, and clinical diagnostics organizations seeking unified LIMS/ELN/SDMS platforms with AI capabilities.